{"id":743759,"date":"2013-09-11T02:15:00","date_gmt":"2013-09-11T02:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/"},"modified":"2023-03-22T00:04:34","modified_gmt":"2023-03-22T04:04:34","slug":"merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/","title":{"rendered":"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      and AstraZeneca (NYSE: AZN) today announced a worldwide licensing<br \/>\n      agreement for Merck\u2019s oral small molecule inhibitor of WEE1 kinase<br \/>\n      (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical<br \/>\n      studies in combination with standard-of-care therapies for the treatment<br \/>\n      of patients with certain types of ovarian cancer.\n    <\/p>\n<p>\n      WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor<br \/>\n      MK-1775 is designed to cause certain tumor cells to divide without<br \/>\n      undergoing normal DNA repair processes, ultimately leading to cell<br \/>\n      death. Preclinical evidence suggests that the combination of MK-1775 and<br \/>\n      DNA damage-inducing chemotherapy agents can enhance anti-tumor<br \/>\n      properties, in comparison to chemotherapy alone.\n    <\/p>\n<p>\n      Under the terms of the agreement, AstraZeneca will pay Merck a $50<br \/>\n      million upfront fee. In addition Merck will be eligible to receive<br \/>\n      future payments tied to development and regulatory milestones, plus<br \/>\n      sales-related payments and tiered royalties. AstraZeneca will be<br \/>\n      responsible for all future clinical development, manufacturing and<br \/>\n      marketing.\n    <\/p>\n<p>\n      \u201cMK-1775 is a strong addition to AstraZeneca\u2019s growing oncology<br \/>\n      pipeline, which already includes a number of inhibitors of the DNA<br \/>\n      damage response,\u201d said Susan Galbraith, head of AstraZeneca\u2019s Oncology<br \/>\n      Innovative Medicines Unit. \u201cThe compound has demonstrated encouraging<br \/>\n      clinical efficacy data and we intend to study it in a range of cancer<br \/>\n      types where there is a high unmet medical need.\u201d\n    <\/p>\n<p>\n      \u201cMerck is committed to advancing potentially meaningful therapeutic<br \/>\n      options promptly for patients with cancer,\u201d said Iain D. Dukes, senior<br \/>\n      vice president and head of licensing and external scientific affairs,<br \/>\n      Merck. \u201cWe are pleased to enter this agreement with AstraZeneca to<br \/>\n      realize the potential of MK-1775 while we focus on advancing our later<br \/>\n      stage oncology programs, MK-3475 and vintafolide.\u201d\n    <\/p>\n<p>\n      The agreement is contingent on expiration or termination of the waiting<br \/>\n      period under the Hart Scott-Rodino Antitrust Improvement Act.\n    <\/p>\n<p>\n      <b>About MK-1775<\/b>\n    <\/p>\n<p>\n      WEE1 is a cell cycle checkpoint protein regulator. Preclinical data<br \/>\n      indicate that disruption of WEE1 may enhance the cell killing effects of<br \/>\n      some anticancer agents. MK-1775 is an investigational orally available<br \/>\n      inhibitor of the cell cycle checkpoint protein WEE1. MK-1775 is being<br \/>\n      evaluated in Phase IIa clinical trials for the treatment of patients<br \/>\n      with P53-deficient ovarian cancer.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=222ed69601ff33224190c33f83eaef5e\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=310641e2f00309e50ecca9b65e25ccf0\">Twitter<\/a>,<br \/>\n      <a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=37ffbad5e20a1af5ddf458e8593dfcc6\">Facebook<\/a><br \/>\n      and <a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=d8d0446d500c350048d8a4cc4b843dd4\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About AstraZeneca<\/b>\n    <\/p>\n<p>\n      AstraZeneca is a global, innovation-driven biopharmaceutical business<br \/>\n      that focuses on the discovery, development and commercialization of<br \/>\n      prescription medicines, primarily for the treatment of cardiovascular,<br \/>\n      metabolic, respiratory, inflammation, autoimmune, oncology, infection<br \/>\n      and neuroscience diseases. AstraZeneca operates in over 100 countries<br \/>\n      and its innovative medicines are used by millions of patients worldwide.<br \/>\n      For more information please visit: <a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.astrazeneca.com&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=www.astrazeneca.com&#038;index=5&#038;md5=41a7194bfa69bf3c245627210e807317\">www.astrazeneca.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50706745&#038;newsitemid=20130911005375&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=d7bed4a835c97f9e334acac8cc72b423\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130911005375r1&#038;sid=sfsite2&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a rel=\"nofollow\" href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20130911005375\/en\/\">http:\/\/www.businesswire.com\/multimedia\/home\/20130911005375\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lappetito, (267) 305-7639<br \/>or<br \/>Investor:<br \/>Carol        Ferguson, (908) 423-4465<br \/>Justin Holko, (908) 423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck\u2019s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumor cells to divide without undergoing normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone. Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee. In addition Merck will be eligible to receive future payments tied to development and regulatory milestones, plus sales-related<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743759","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck\u2019s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumor cells to divide without undergoing normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone. Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee. In addition Merck will be eligible to receive future payments tied to development and regulatory milestones, plus sales-related\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/\",\"name\":\"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx\",\"datePublished\":\"2013-09-11T02:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck\u2019s oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumor cells to divide without undergoing normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone. Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee. In addition Merck will be eligible to receive future payments tied to development and regulatory milestones, plus sales-related","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:34+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/","name":"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx","datePublished":"2013-09-11T02:15:00+00:00","dateModified":"2023-03-22T04:04:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130911005375r1&sid=sfsite2&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-astrazeneca-enter-license-agreement-for-investigational-oral-wee1-kinase-inhibitor-therapy-for-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1047db76-81ae-4d14-9fbf-038e3788b8fd","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2013\/09\/1\/AstraZeneca_logo-5B1-5D.jpg","size":"19963","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2013\/09\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743759\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743759"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}